Details of the Drug

General Information of Drug (ID: DML2CPW)

Drug Name
VAY736
Indication
Disease Entry ICD 11 Status REF
Pemphigus vulgaris EB40 Phase 2 [1]
Rheumatoid arthritis FA20 Phase 2 [2]
Sjogren syndrome 4A43.20 Phase 2 [3]
Drug Type
Antibody
Cross-matching ID
TTD ID
D09SQM
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-cell-activating factor receptor (TNFRSF13C) TT7NJSE TR13C_HUMAN Not Available [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT02137889) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients. U.S. National Institutes of Health.
4 National Cancer Institute Drug Dictionary (drug id 762784).